Arcturus Therapeutics Holdings Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
DE
Business Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA,
Mailing Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA,
Phone
8589002660
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 10-K Annual financial report | March 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 8, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | December 30, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 3 Initial insider ownership report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
Annual Reports
10-K
March 3, 2026
- Advanced ARCT-810 into Phase 2 and ARCT-032 through Phase 1b, achieving crucial clinical milestones.
- Strengthened strategic partnership with CSL Seqirus for next-generation mRNA vaccines, providing non-dilutive funding and leveraging commercial expertise.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.